For direct compression of LISATHYONE into uncoated tablets, the pharma-grade levothyroxine sodium API is first characterized by laser diffraction method USP 429 for particle size distribution; micronized material is typically controlled at D90 ≤ 10 μm unless the supplier certificate of analysis states otherwise. The powder is screened through a 500 μm sieve to break soft agglomerates before geometric dilution. A two-stage premix is prepared in a 4 L cube blender at 20 rpm; the first stage blends 1 part LISATHYONE with 9 parts lactose monohydrate for 5 min, and the second stage adds the remaining diluent to the intended 120 mg core weight. Because LISATHYONE is a narrow-therapeutic-index thyroid hormone API, blend uniformity is sampled at 10 points using ASTM E2810-19 and should show RSD ≤ 5.0% before compression. The direct compression formulation uses microcrystalline cellulose at 60–70 wt%, crospovidone at 2–4 wt%, and magnesium stearate at 0.5–1.0 wt%; the lubricant is added last and mixed for 3 min to avoid overlubrication. If ambient relative humidity exceeds 60%, the pre-lubricated blend is dried at 40 °C for 2 h and re-screened through a 500 μm sieve. Compression is performed on a Korsch XL 100 rotary press with 10 stations using 6 mm round standard concave tooling at a target hardness of 30–60 N and press speed of 30–60 rpm. Tablet thickness tolerance is set at ± 0.2 mm, and friability is tested according to USP 1216 with a limit of ≤ 1.0%. Dissolution is evaluated with USP 711 Apparatus 2 at 37 ± 0.5 °C; the medium and paddle speed are validated against the LISATHYONE monograph and must discriminate between formulation variants. Content uniformity follows USP 905 with an acceptance value ≤ 15.0. The terminal dosage form is an uncoated or film-coated tablet packed in amber glass or Al/Al blister with desiccant; the final blend bulk density is recorded to track batch-to-batch variance.

What Limits Roller Compaction Throughput for LISATHYONE Dry Granulation?

Cohesive micronized particles of LISATHYONE and its low bulk density reduce ribbon tensile strength, so dry granulation requires a roller compactor with side sealing to prevent powder leakage. A Gerteis Mini-Pactor with 120 mm roll width is operated at roll force of 8–12 kN/cm; ribbon solid fraction is maintained between 0.55 and 0.70 to produce granules with acceptable flow while retaining compressibility. The powder pre-blend contains microcrystalline cellulose at 50–60 wt%, pregelatinized starch at 15–20 wt%, croscarmellose sodium at 3–5 wt%, and magnesium stearate at 0.5 wt%. Ribbons are milled through a 0.8 mm screen at 120 rpm; the 500–800 μm granule fraction is selected for capsule filling or tableting. Because roller compaction can cause segregation and assay drift in low-dose APIs, granule blend uniformity is checked by ASTM E2810-19 and USP 905 with RSD ≤ 5.0%. Published data specific to LISATHYONE roller compaction is limited; a bracketing study at 0.25 wt%, 0.50 wt%, and 0.75 wt% magnesium stearate is required before setting the final lubricant level. The terminal product is a dry granulate or compressed tablet with moisture content ≤ 2.0% by USP 731.

When LISATHYONE is formulated as single-dose oral granules for sachet filling, low-shear fluid-bed granulation is selected only after aqueous binder compatibility is confirmed. A hypromellose 5 cP binder solution at 3 wt% is sprayed at 5–10 g/min onto a dry mixture of mannitol, pregelatinized starch, and LISATHYONE in a Glatt GPCG 3.1 fluid-bed granulator. Inlet air temperature is maintained at 45 ± 3 °C, product temperature at 30 ± 2 °C, and spraying air pressure at 1.0–1.5 bar. The granulation endpoint is controlled by loss on drying with a limit of ≤ 1.5% by USP 731. Dried granules are milled through a 0.6 mm screen and filled into aluminum/polyethylene sachets under 20% RH or lower. Each sachet contains the labeled microgram strength of LISATHYONE and is checked by USP 905 for dosage uniformity with an acceptance value ≤ 15.0. Disintegration of the granules is tested in 5 mL water at 25 °C; no visible agglomerates should remain after 2 min of gentle swirling. The completed sachet is packed with silica gel desiccant and aluminum foil laminate to limit moisture ingress; package integrity is verified under 40 °C/75% RH ICH storage conditions.

Capsule Filling, Weight Sorting, and Dissolution Matching for Low-Fill-Weight LISATHYONE Powder Blends

Low-fill-weight LISATHYONE powder blends for hard gelatin or HPMC capsules require a flowable pre-blend with minimal segregation potential. A premix containing 0.5% colloidal silicon dioxide and 60 wt% mannitol is passed through a 0.5 mm cone mill before filling on a Zanasi 40E intermittent-motion capsule filler with dosing disk size 0 or 1 and plug height of 2–3 mm. The target fill weight is 60–80 mg; acceptance limits are ± 5.0% for individual capsules and ± 2.5% for the mean fill weight. Powder flow is characterized by USP 1174 and should show Carr index ≤ 25 before filling; segregation potential is checked by sampling at start, middle, and end of the filling run with USP 905 content uniformity. Dissolution matching against the reference listed drug is evaluated with USP 711 using an f2 metric ≥ 50 as described in FDA guidance. Capsule shells are selected for low moisture content of 13–16% for gelatin and low peroxide content; HPMC capsules are substituted if gelatin crosslinking is observed in the dissolution medium. The terminal product is a two-piece hard capsule packed in Al/Al cold form blisters with desiccant.

When LISATHYONE Is Formulated as a Ready-to-Use Injection, Terminal Sterilization Is Replaced by Aseptic Filtration Only After Heat-Lability Is Confirmed

LISATHYONE sodium is dissolved in Water for Injection under nitrogen overlay to keep dissolved oxygen below 0.5 mg/L measured with an optical oxygen probe. The solubility of LISATHYONE sodium is pH-dependent; alkaline media may improve dissolution but can accelerate degradation above pH 8.0. Forced degradation is therefore run at pH 6.5, 7.0, 7.5, and 8.0 using ICH Q1A conditions before selecting the final buffer. A 0.05 M phosphate or citrate buffer is used only after total impurities remain below 0.5% at the selected pH; if no stable pH range is identified in solution, lyophilization is triggered. The pH is adjusted with 0.1 M sodium hydroxide or 0.1 M hydrochloric acid and checked to ± 0.05 pH units. The solution is cooled to 5 ± 2 °C during filtration to reduce hydrolysis rate. The sterilizing filter train uses a 0.45 μm PVDF prefilter followed by a 0.22 μm sterilizing-grade PES filter; filter integrity is tested by bubble point and diffusion per ASTM F838-20 before and after filtration. Terminal sterilization at 121 °C for 15 min is not applied because thermal stress can displace iodine and raise total impurities; aseptic processing is validated by media fills with 5,000 units and zero contaminated units, consistent with 21 CFR 211.167 and EU GMP Annex 1. Tonicity is adjusted with sodium chloride to 290–310 mOsm/kg measured by vapor pressure osmometry. The finished injection is filled into amber borosilicate Type I glass vials under nitrogen overlay; residual headspace oxygen is controlled to ≤ 1.0% by an electrochemical analyzer. Particulate matter is measured by USP 788 light obscuration; for small-volume parenterals, acceptance is ≤ 6,000 particles ≥ 10 μm and ≤ 600 particles ≥ 25 μm per container. Bacterial endotoxin is controlled per USP 85 gel-clot method using the monograph limit for LISATHYONE; if no monograph limit is established, the limit is based on maximum daily dose. Container closure integrity is verified by USP 1207 vacuum decay at −200 mbar and by dye ingress on a sampling plan. Published data specific to LISATHYONE ready-to-use injection stability is limited; a 14-day accelerated study at 25 °C/60% RH and 40 °C/75% RH is used to bracket the formulation.

Alternatively, a lyophilized LISATHYONE injection is produced when aqueous solution stability is insufficient for liquid shelf storage. The pre-lyophilization solution contains LISATHYONE sodium, mannitol at 4–6% w/v as a crystalline bulking agent, and trehalose dihydrate at 1–2% w/v as a lyoprotectant. The solution is filtered through a 0.22 μm PES filter and filled at 5 ± 0.2 mL into 10 mL Type I glass vials. Freeze-drying microscopy is used to measure collapse temperature for each formulation variant; primary drying shelf temperature is set 2–5 °C below collapse temperature, typically −20 to −10 °C at a chamber pressure of 60–120 μbar. Primary drying is held for 10–18 h until the Pirani and capacitance manometer readings converge, indicating completion of the sublimation front. Secondary drying at 25 °C for 8–12 h reduces residual moisture to ≤ 2.0% by USP 921 Karl Fischer titrimetry. Cake collapse, shrinkage, meltback, or discoloration is rejected by visual inspection under a light box; the accepted cake is intact and white to off-white. The lyophilized cake is reconstituted with 5 mL WFI at 25 °C and must dissolve within 2 min without visible particulates. Sterility is tested by USP 71 direct transfer using 20 vials to soybean-casein digest medium and fluid thioglycollate medium. Container closure integrity is verified after lyophilization by USP 1207 laser-based headspace moisture analysis; the terminal product is a sterile lyophilized powder for injection with a residual moisture specification.

Oral Reconstitution Granules Must Meet Disintegration and Dose-Weight Uniformity Under High-Moisture Storage

LISATHYONE granules for oral reconstitution are built on sucrose spheres with a 250–350 μm core size using a bottom-spray fluid-bed coater. A binder solution of hypromellose 3.0 wt% is sprayed at 2–5 g/min; after spraying, the granules are dried to ≤ 1.5% moisture by USP 731. The sachet fill weight is typically 200 mg, combining LISATHYONE with citric acid, sodium bicarbonate, and a sugar-free filler if requested. Upon reconstitution in 5 mL water at 25 °C, the granules should disperse within 2 min with no visible agglomerates. Dose-weight uniformity is measured by USP 905 with an acceptance value ≤ 15.0; fill weight variation is controlled to ± 5.0% for individual sachets. Dissolution is performed with USP 711 Apparatus 2 to confirm no floating or clumping occurs after reconstitution. The sachet material is a PET 12 μm / Al 9 μm / PE 50 μm laminate with a water vapor transmission rate ≤ 0.01 g/m²·day; each sachet is heat-sealed under 20% RH and packed with silica gel desiccant. The terminal product is a single-dose oral reconstitution granule in a moisture-resistant sachet.